AIM ImmunoTech (AIM) AI Stock Analysis

• Market Cap: $7.08M
• Dividend Yield: N/A
• Average Volume (3M): 10.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: -24.35%
• EPS Growth: 61.00%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 764,188
• 10 Day Avg. Volume: 4,505
• 30 Day Avg. Volume: 10,392
• PEG Ratio: -1.92
• Price to Book (P/B): -165.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.45
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 8.79
• Enterprise Value/Gross Profit: 81.83
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $5.25
• Price Target Upside: -43.91% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: $9.00 ▼(-3.85%Downside)

AIM ImmunoTech's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenue, persistent losses, and negative cash flow. The technical analysis provides some short-term optimism, but the longer-term trends remain bearish. Valuation concerns are significant due to the negative P/E ratio and lack of dividend yield. The recent NYSE noncompliance notification further underscores the financial challenges facing the company.

Positive Factors

Analyst Rating

The analyst maintains a BUY rating for AIM, seeing large upside opportunities that balance high risks with high growth prospects.

Clinical Trials

Positive data from a Phase 2 study for Ampligen as a therapeutic for patients with post-COVID conditions could boost stock performance.

Negative Factors

Corporate Governance

Dissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.

Stock Listing

The company's stock has been delisted from NYSE American and is now trading on Pink Open Market, which might impact investor confidence.

AIM ImmunoTech Business Overview & Revenue Model

Company Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

How the Company Makes Money

AIM ImmunoTech generates revenue primarily through the development and commercialization of its proprietary drug, Ampligen. The company earns money by partnering with other pharmaceutical companies for the distribution and sale of Ampligen in various markets. Additionally, AIM engages in licensing agreements and collaborative research projects to fund and advance the clinical development of its therapies. The company also seeks government grants and clinical trial funding to support its research endeavors, which contributes to its revenue stream.

AIM ImmunoTech Financial Statement Overview

Summary

AIM ImmunoTech is facing significant financial hurdles characterized by declining revenue, persistent losses, and negative cash flow. While the company has managed its debt levels well, the lack of equity and negative cash flow raise concerns about its long-term financial sustainability.

Income Statement

AIM ImmunoTech has demonstrated declining revenue with negative net income over the past years. Despite a slight improvement in gross profit, EBIT and EBITDA margins remain negative, indicating ongoing operational challenges and a lack of profitability.

Balance Sheet

The company has a strong cash position relative to its total assets, but it faces challenges with zero stockholders' equity, indicating potential financial distress. The absence of debt provides some stability, yet the lack of equity suggests limited growth capacity.

Cash Flow

Operating cash flow remains negative, reflecting persistent cash burn. While the company has managed to secure financing, free cash flow remains negative, and growth in free cash flow is absent, indicating ongoing liquidity challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	170.00K	202.00K	141.00K	135.00K	163.00K
Gross Profit	139.00K	160.00K	-19.78M	-715.00K	-643.00K
EBITDA	-16.49M	-31.68M	-19.87M	-18.25M	-13.02M
Net Income	-17.32M	-28.96M	-21.09M	-21.51M	-16.26M
Balance Sheet
Total Assets	8.61M	19.38M	40.49M	57.70M	64.58M
Cash, Cash Equivalents and Short-Term Investments	3.98M	13.07M	34.19M	48.27M	39.00M
Total Debt	2.94M	718.00K	837.00K	149.00K	2.29M
Total Liabilities	9.93M	9.15M	2.02M	820.00K	3.29M
Stockholders Equity	-1.32M	10.23M	38.47M	56.88M	61.29M
Cash Flow
Free Cash Flow	-14.91M	-21.85M	-16.38M	-14.60M	-10.96M
Operating Cash Flow	-14.89M	-21.27M	-16.11M	-13.96M	-10.37M
Investing Cash Flow	4.71M	-832.00K	10.99M	-631.00K	-9.16M
Financing Cash Flow	6.44M	485.00K	80.00K	8.19M	56.56M

AIM ImmunoTech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.36
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Positive. The current price of 9.36 is above the 20-day moving average (MA) of 8.89, above the 50-day MA of 8.61, and below the 200-day MA of 15.90, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 55.10 is Neutral, neither overbought nor oversold. The STOCH value of 58.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIM.

AIM ImmunoTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
AIM	45 Neutral	$7.08M	―	-3138.91%	―	-24.35%	61.00%
APLM	42 Neutral	$6.36M	―	-233.67%	―	―	-1786.46%
ACXP	39 Underperform	$11.74M	―	-285.79%	―	―	23.65%
INDP	27 Underperform	$7.37M	―	-259.00%	―	―	11.97%
PMCB		$7.55M	1.46	45.44%	―	―	―
OCEA		$1.73M	―		―	―	―

AIM ImmunoTech Corporate Events

AIM ImmunoTech Faces NYSE Noncompliance Notification

On June 17, 2025, AIM ImmunoTech Inc. received a notification from NYSE American LLC indicating noncompliance with the minimum stockholders’ equity requirements due to a stockholders’ deficit of negative $3.9 million as of March 31, 2025, and consistent losses over the past five fiscal years. Despite a previous warning in December 2024, the company has until June 11, 2026, to regain compliance, and its stock continues to trade on the NYSE American. The notification does not impact the company’s operations or SEC reporting requirements.

The most recent analyst rating on (AIM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.